MARAVAI LIFESCIENCES HOLDINGS, INC. current report, 02 September 2021

Full document

Business Context and Reporting Period

Maravai LifeSciences Holdings, Inc. filed a Form 8-K dated September 2, 2021, with the report signed on September 3, 2021. The filing concerns the disposition of the Protein Detection business segment and an amendment to TriLink Biotechnologies’ supply agreement with Pfizer and BioNTech.

Key Financial and Operating Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, purchase price, or other quantitative financial metrics.

  • The Protein Detection business segment, operated through Vector Laboratories, Inc., was sold to Voyager Group Holdings, Inc., an entity affiliated with Thompson Street Capital Partners VI, L.P.
  • The filing states that the disposition did not involve a significant business.
  • Vector Laboratories now operates as an independent, privately held business.

Material Changes Versus the Prior Comparable Period

  • On September 2, 2021, the Company completed the previously announced sale of Vector Laboratories.
  • Lisa Sellers, Ph.D., who headed Vector Laboratories, is no longer employed by Maravai.
  • Amendment No. 1 to the merger agreement adjusted certain purchase price adjustment provisions, including treatment of facility-relocation payments and specified accounts payable.
  • The parties agreed to treat September 2, 2021, as the closing date for economic and other purposes to the fullest extent permitted by law, even if California processing delays resulted in a later legal effective date.
  • An amendment to the Pfizer and BioNTech supply agreement, effective June 6, 2021, modifies billing, pricing, and payment terms, including a change from milestone-based invoicing to invoicing upon product shipment.

Guidance, Outlook, Risks, Contingencies, and Unusual Items

  • No financial guidance or formal outlook is provided.
  • The filing does not disclose the sale consideration or expected gain or loss on disposal.
  • Purchase price adjustments remain subject to the amended merger agreement provisions.
  • Some exhibit schedules were omitted and may be furnished to the SEC upon request, subject to potential confidential treatment.
  • Certain portions of the Pfizer and BioNTech supply agreement amendment were redacted as confidential information.

Important Facts for Investors to Verify

  1. Final proceeds, purchase price adjustments, and any accounting gain or loss from the Vector Laboratories sale.
  2. The financial contribution of the divested Protein Detection segment and the effect of its removal on future reported results.
  3. The economic impact of changing Pfizer and BioNTech invoicing from milestones to product shipments.
  4. Whether the amended supply agreement changes pricing, volume commitments, payment timing, or concentration risk.
  5. The final legal closing date under California law and any related accounting or reporting consequences.